Shockwave Medical and CRISPR Therapeutics Beat Expectations in Q1 Earnings, Ocular Therapeutix Falls Short
- May 08th, 2023
- 461 views
Shockwave Medical, Inc. (Nasdaq: SWAV) reported better-than-expected Q1 earnings, with an EPS of $1.03 versus the consensus estimate of $0.81. In after-hours trading, SWAV is up $10.04 (+3.65%) and is currently trading at $285.00.
On the other hand, CRISPR Therapeutics AG (Nasdaq: CRSP) reported a Q1 loss of $0.67 per share, which was better than the consensus estimate of a loss of $1.70 per share. As a result, in after-hours trading, CRSP is up $0.54 (+0.96%) and is currently trading at $56.50.
Finally, Ocular Therapeutix, Inc. (Nasdaq: OCUL) reported a Q1 loss of $0.39 per share, worse than the consensus estimate of a loss of $0.26 per share. As a result, in after-hours trading, OCUL is down $0.30 (-4.69%) and is currently trading at $6.10.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login